Crisci et al. from CorEvitas. Alcohol, esp moderate use, associated lower CDAI. Most likely explanation appears to be re https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg […]
Postmenopausal women using hormone therapy were more likely to develop autoimmune diseases compared with nonusers, research presented at the Annual
Nationwide Study Exposes Thrombosis Burden in SLE. 27 Oct 2025. Rheumatology · View All News. Hospital burden of thrombotic events
Current American College of Rheumatology, European Alliance of Associations for Rheumatology, and Kidney Disease: Improving Global Outcomes …
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce
… Rheumatology (ACR) Convergence in Chicago, Illinois taking place from October 24-29, 2025. “The POETYK PsA-1 Week 52 data and
… Rheumatology Convergence 2025 … Rheumatology Convergence 2025. “Data from the CARLYSLE study shows that obe-cel has the potential to
Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual …
(NASDAQ: TNXP) presented clinical trial data for its fibromyalgia treatment Tonmya at the 2025 American College of Rheumatology Convergence in
… Rheumatology (ACR) Convergence, held October 24–29, 2025, in Chicago … Rheumatology criteria for fibromyalgia. Treatment with Tonmya …
Kymera Therapeutics (NASDAQ: KYMR) presented new preclinical data for KT-579, an oral IRF5 degrader, at the American College of Rheumatology
The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product,
We collected audit data from patients aged 16 years and older who attended specialist rheumatology centres in England and Wales
… Rheumatology (ACR) Convergence 2025, currently underway in Chicago. The featured poster highlights findings from Citryll’s Phase I clinical trial …
Hospitals and specialized rheumatology centers provide improved access to clinical care, which strengthens treatment uptake across the region. In …
For rheumatologists, these data reinforce upadacitinib’s role as a viable and durable option for patients across multiple lines of therapy,
claire-daien-md-phd. Advertisement. Claire Daien, MD, PhD. Prof of Rheumatology at Université de Montpellier. Articles by Claire Daien, MD, PhD …
Upadacitinib is a Double Edged Vascular Sword in GCA tammytilley@gm… Sun, 10/26/2025 – 23:41 Education/ACR/EULAR Anti-Rheumatic Rx Labs/Biomarkers Steroids Vasculitis
#ACR25 Abstr#0773 Anti-MDA5 ab is assoc. with progressive DM-ILD. But MDA5 expression is also upregulated in IPF. Any ne https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg
What is the #frequency of #CTD #ILD in #USA? Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts 56-65 yrs,
Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMb https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john… Sun, 10/26/2025
AI Scribes Found their Favorite Doctors tammytilley@gm… Sun, 10/26/2025 – 20:53 Education/ACR/EULAR General Rheumatology Dr. Aurelie Najm discusses abstract 0189,
Next Generation T-Cell Engager: The Future tammytilley@gm… Sun, 10/26/2025 – 19:29 Education/ACR/EULAR Novel Rx Dr. Alfred Kim reviews abstract 0001
High prevalence of sleep related symptoms in PsA pts! -Snoring 53% -Morning fatigue 68% -Obstructive Sleep Apnea in https://pbs.twimg.com/profile_images/1800478984926334976/yyyPLP4A_normal.jpg john+RNV2@john…
#ACR25 Abstr#663 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 8 #SLE patients in Phase 1. Ad https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg john+RNV2@john…
